Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement

European Neurology

Volumn 70, Issue 1-2, 2013, Pages 65-69

  Kokubun, Norito ^a   Sada, Tsubasa ^a   Yuki, Nobuhiro ^b   Okabe, Momoka ^a   Hirata, Koichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Grip strength; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; GRIP STRENGTH; HUMAN; MALE; NERVE CONDUCTION; PRIORITY JOURNAL; TREATMENT OUTCOME; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; HOME MONITORING; IMMUNOTHERAPY; MIDDLE AGED; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; SYMPTOM ASSESSMENT;

ADULT; HAND STRENGTH; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84883140693     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000350287     Document Type: Article

References (13)

1. van den Bergh PY, Hadden RDM, Bouche P, et al: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17: 356-363.
2. Hughes RAC, Donofrio P, Bril V, et al: Intravenous immune globulin (10% caprylatechromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144.
3. RMC Trial Group: Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8: 158-164.
4. van Schaik IN, Winer JB, De Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;2:CD001797.
5. van Schaik IN, Eftimov F, van Doorn PA, et al: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 245-253.
6. Latov N, Deng C, Dalakas MC, et al: Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 802-807.
7. Vanhoutte EK, Latov N, Deng C, et al: Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIg - the ICE study. Eur J Neurol 2013;20:748-755.
8. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-1077.
9. Hughes RAC, Bensa S, Willison H, et al: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201.
10. Brannagan TH 3rd: Current diagnosis of CIDP: the need for biomarkers. J Peripher Nerv Syst 2011; 16(suppl 1):3-13.
11. Pollard JD, Armati PJ: CIDP - the relevance of recent advances in schwann cell/axonal neurobiology. J Peripher Nerv Syst 2011; 16: 15-23.
12. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al: Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009; 66: 597-603.
13. van Doorn PA, Kuitwaard K, Jacobs BC: Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst 2011; 16(suppl 1):38-40.